72,779 Shares in Certara, Inc. (NASDAQ:CERT) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in Certara, Inc. (NASDAQ:CERT) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 72,779 shares of the company’s stock, valued at approximately $852,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geneva Capital Management LLC grew its stake in shares of Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after acquiring an additional 37,392 shares during the period. Dimensional Fund Advisors LP boosted its position in Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after purchasing an additional 273,095 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 9.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after purchasing an additional 248,448 shares in the last quarter. Daventry Group LP raised its position in shares of Certara by 153.0% in the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares during the period. Finally, Bamco Inc. NY lifted its stake in shares of Certara by 1.4% during the 1st quarter. Bamco Inc. NY now owns 1,085,950 shares of the company’s stock valued at $19,417,000 after buying an additional 15,000 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Finally, Barclays cut their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $15.92.

Certara Stock Performance

NASDAQ:CERT opened at $10.36 on Friday. The stock has a market cap of $1.67 billion, a P/E ratio of -51.80, a PEG ratio of 5.00 and a beta of 1.51. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $10.79 and its two-hundred day moving average price is $13.22. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.06 earnings per share. As a group, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Buying and Selling at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 33.94 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.